Exploratory Clinical Study of Neoadjuvant Immunotherapy Combined With Chemotherapy in Malignant Melanoma of Nasal and Paranasal Mucosa

Sinonasal mucosal malignant melanoma (SNMM) is a nasal and paranasal sinus malignancy with a low incidence and extremely poor prognosis, exhibiting specificity in Asian populations. For resectable SNMM, the efficacy of neoadjuvant immunotherapy is unclear. This prospective clinical study aims to explore the survival prognosis of neoadjuvant immunotherapy combing radiochemotherapy after Endoscopic Surgery for resectable SNMM.

Trial Details

NCT ID
NCT07614828
Phase
PHASE2
Sponsor
Eye & ENT Hospital of Fudan University
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • neoadjuvant immunotherapy combing radiochemotherapy before Endoscopic Surgery
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Histopathologically confirmed diagnosis of malignant melanoma of the nasal cavity and paranasal sinuses.
  • T stage of T3 or T4a.
  • Age ≥18 years.
  • No distant metastasis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →